Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DM1MFTZ)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
beta-CCM; Methyl beta-carboline-3-carboxylate; beta-Carboline-3-carboxylic acid methyl ester; 69954-48-9; 3-Carbomethoxy-beta-carboline; UNII-I2A008F6YL; methyl 9H-pyrido[3,4-b]indole-3-carboxylate; CHEMBL453066; CHEMBL268191; I2A008F6YL; Methyl 9H-Pyrido(3,4-b)indole-3-carboxylate; methyl 9H-beta-carboline-3-carboxylate; 9H-beta-Carboline-3-carboxylic acid methyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, methyl ester; C13H10N2O2; Beta CCM; Lopac-E-002; Biomol-NT_000273; AC1L32LA; Lopac0_000523; SCHEMBL1066725
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
